Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban.
Massimo MapelliIrene MattavelliElisabetta SalvioniNicolò CapraAlice BonomiGaia CattadoriBeatrice PezzutoJeness CampodonicoArianna PiottiAlessandro NavaMassimo PiepoliDamiano MagrìStefania PaolilloUgo CorràRosa RaimondoRocco LagioiaCarlo VignatiRoberto BadagliaccaPasquale Perrone FilardiMichele SenniMichele CorrealeMariantonietta CicoiraMarco MetraMarco GuazziGiuseppe LimongelliGianfranco ParatiFabiana De MartinoFrancesco BanderaMaurizio BussottiFederica ReCarlo M LombardiAngela B ScardoviSusanna SciomerAndrea PassantinoMichele EmdinCaterina SantolamazzaEnrico PernaClaudio PassinoGianfranco SinagraPiergiuseppe Agostoninull nullPublished in: Journal of clinical medicine (2023)
this study confirms the prognostic accuracy of the MECKI score in HFrEF patients with NVAF treated with edoxaban, showing improved predictive power compared to VKA-treated patients.
Keyphrases
- atrial fibrillation
- heart failure
- newly diagnosed
- end stage renal disease
- venous thromboembolism
- ejection fraction
- oral anticoagulants
- prognostic factors
- peritoneal dialysis
- direct oral anticoagulants
- left atrial
- percutaneous coronary intervention
- left ventricular
- aortic valve
- coronary artery disease
- left atrial appendage
- acute heart failure
- patient reported